Compare F.N.B. Corporation Common Stock (FNB) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F.N.B. Corporation Common Stock vs Novavax Inc — how do they compare? F.N.B. Corporation Common Stock trades at $16.96 (market cap $6.03B), while Novavax Inc trades at $12.43 (market cap $2.08B). The key difference: F.N.B. Corporation Common Stock is far larger — about 2.9× Novavax Inc's market cap, and F.N.B. Corporation Common Stock pays a 3.07% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold F.N.B. Corporation Common Stock for 0 Days and Novavax Inc for 59 Days on average.
| FNB | NVAX | |
|---|---|---|
Market Cap | $6.03B | $2.08B |
Volume | 7,117,178 | 8,501,139 |
Sector | Financials | Health |
52-Week High | $19.49 | $12.82 |
52-Week Low | $14.65 | $6.22 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $10.52B | $1.66B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNB trades at $17.05, down 0.76% on the day, with a neutral technical signal. The stock shows solid fundamentals with a P/E of 10.15 and P/B of 0.89, indicating potential undervaluation. Recent earnings have been mixed, with Q2 2026 beating estimates but Q1 missing. Revenue remains stable at $1.77 billion for 2025, with a strong net income margin of 33.04%. Analyst sentiment is positive, with 13 buy ratings and a consensus price target of $20.80.
The outlook for FNB is cautiously optimistic, supported by strong profitability and a favorable analyst consensus. Key opportunities include potential upside to the price target and consistent dividend payments. Risks involve earnings volatility, as seen in recent quarters, and competitive pressures in the banking sector. Investors should weigh the attractive valuation against execution risks and market conditions.
Novavax (NVAX) trades at $12.82, up 1.26% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats and strategic pivots toward its Matrix-M adjuvant platform and partnerships, such as with Sanofi for COVID-19 vaccines, highlight operational progress. However, negative cash flows and a net loss in 2026 projections underscore financial volatility amid transitioning revenue streams.
The outlook balances near-term catalysts from vaccine approvals and partnership momentum against persistent cash burn and competitive pressures. Investors face opportunity in undervalued metrics like a low P/E of 3.14, but risks include execution hurdles and dependency on successful licensing deals to achieve sustainable profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About F.N.B. Corporation Common Stock
F.N.B. Corporation is a diversified financial services holding company headquartered in Pittsburgh, Pennsylvania, operating through its lead subsidiary, First National Bank of Pennsylvania. It provides commercial banking, consumer banking, wealth management, and insurance through more than 350 banking offices across seven states and Washington, D.C.
Read more on FNB →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
